The results of this study suggested that serum transferrin levels might be positively associated with the risk of estrogen receptor-negative (ER-negative) breast cancer, although no significant effect was observed on the risk of breast cancer in general or its ER-positive subtypes [146]. This evidence concerns the gene ESR1 and breast carcinoma.